hydroxyurea has been researched along with Innate Inflammatory Response in 60 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hydroxyurea has been shown to reduce leukocyte counts, decrease inflammatory cytokines, and limit organ inflammation in ischemia-reperfusion models." | 8.12 | The effects of hydroxyurea on proinflammatory cytokine and tissue histopathology in an experimental sepsis model. ( Ergil, J; Kulturoglu, G; Kulturoglu, MO; Onder, EO; Yalcindag, A, 2022) |
| " Higher Epo levels were seen in patients receiving hydroxyurea (HU), but no correlation with oxygenation, hemolysis, renal function, or inflammation was observed." | 5.19 | Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin. ( Ballas, SK; Caro, J; McKenzie, SE; Pulte, ED, 2014) |
| " Hydroxyurea has been shown to reduce leukocyte counts, decrease inflammatory cytokines, and limit organ inflammation in ischemia-reperfusion models." | 4.12 | The effects of hydroxyurea on proinflammatory cytokine and tissue histopathology in an experimental sepsis model. ( Ergil, J; Kulturoglu, G; Kulturoglu, MO; Onder, EO; Yalcindag, A, 2022) |
| "SCD patients, in steady state and asymptomatic for pulmonary hypertension, were studied stressing on hydroxyurea therapy, serum ferritin, urinary albumin creatinine ratio (UACR), high-sensitivity C-reactive protein (hs-CRP) and sFas/sFasL levels." | 3.83 | Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease. ( Adly, AA; Andrawes, NG; Eladawy, R; Ismail, EA; Mahmoud, MM, 2016) |
| " In a murine model of arachidonic acid-induced ear inflammation, the LTA(4)H inhibitor, JNJ-26993135 (1-[4-(benzothiazol-2-yloxy)-benzyl]-piperidine-4-carboxylic acid), dose-dependently inhibited ex vivo LTB(4) production in blood, in parallel with dose-dependent inhibition of neutrophil influx (ED(50), 1-3 mg/kg) and ear edema." | 3.74 | Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. ( Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Jiang, X; Karlsson, L; Lundeen, KA; Rao, NL; Riley, JP; Williams, KN; Xue, X, 2007) |
| " Treatment of the mice with zileuton or montelukast reduced the spinal cord inflammation and tissue injury, neutrophil infiltration, TNF-alpha, COX-2 and pERK1/2 expression, PGE(2) and LTB(4) production, and apoptosis." | 3.74 | Effects of zileuton and montelukast in mouse experimental spinal cord injury. ( Bramanti, P; Caminiti, R; Cuzzocrea, S; Di Paola, R; Genovese, T; Mazzon, E; Muià, C; Rossi, A; Sautebin, L, 2008) |
| "Capsaicin cough-reflex sensitivity and the number of BAL neutrophils were increased 6 hours after stimulus application, decreasing to control levels by 24 hours." | 3.74 | Effect of pressure stress applied to the airway on cough-reflex sensitivity in Guinea pigs. ( Fujimura, M; Hara, J; Kasahara, K; Kita, T; Myou, S; Ohkura, N; Oribe, Y; Ueda, A; Yasui, M, 2008) |
| "The results indicate that both Zafirlukast and Zileuton reduced the reported DCS symptoms, pulmonary edema, pleural and bronchoalveolar lavage protein levels, white blood cell counts in the pleural and bronchoalveolar lavage, and leukotriene levels in the bronchoalveolar lavage vs." | 3.74 | Pharmacological intervention to the inflammatory response from decompression sickness in rats. ( Butler, BD; Little, T, 2008) |
| "The importance of leukotrienes as mediators of inflammation and bronchoconstriction was examined with two recently described 5-lipoxygenase inhibitors, zileuton and A-78773." | 3.68 | Preclinical and clinical activity of zileuton and A-78773. ( Bell, RL; Brooks, DW; Carter, GW; Hansen, R; Lanni, C; Malo, PE; Rubin, P; Stewart, AO, 1993) |
| "Hydroxyurea treated group was on dosage more than 20 mg/kg/day." | 2.80 | Omega 3 (n-3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease. ( Daak, AA; Elbashir, LM; Elbashir, MI; Elderdery, AY; Ghebremeskel, K; Mariniello, K; Mills, J; Scarlett, G, 2015) |
| "Hydroxyurea was associated with statistically significantly lower rates of initial and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants who were asymptomatic at enrollment had less dactylitis as well as fewer hospitalizations and transfusions if treated with hydroxyurea." | 2.77 | Impact of hydroxyurea on clinical events in the BABY HUG trial. ( Alvarez, O; Files, BA; Iyer, R; Kalpatthi, R; Lebensburger, J; Luo, Z; Miller, ST; Seaman, P; Thompson, B; Thornburg, CD; Wang, WC; Ware, RE, 2012) |
| "To date, sickle cell disease has been cured by hematopoietic stem cell transplantation in approximately 1,000 people, most of whom were children, and significantly ameliorated by gene therapy in a handful of subjects who have only limited follow-up thus far." | 2.61 | Emerging disease-modifying therapies for sickle cell disease. ( Carden, MA; Little, J, 2019) |
| "The root cause of sickle cell disease is a single beta-globin gene mutation coding for the sickle beta-hemoglobin chain." | 2.44 | Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. ( Steinberg, MH, 2008) |
| "Chronic inflammation is believed to play an important role in the development and disease progression of polycythemia vera (PV)." | 1.91 | The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment. ( Andersen, LO; Christensen, JJE; Christensen, SF; Eickhardt-Dalbøge, CS; Ellervik, C; Fuursted, K; Hasselbalch, HC; Ingham, AC; Kjær, L; Knudsen, TA; Larsen, MK; Nielsen, HV; Nielsen, XC; Olsen, LR; Skov, V; Stensvold, CR, 2023) |
| "Zileuton and LY294002 were used to inhibit expression of 5-LOX and Akt, respectively." | 1.62 | 5-Lipoxygenase inhibition reduces inflammation and neuronal apoptosis via AKT signaling after subarachnoid hemorrhage in rats. ( Chen, H; Deng, Y; Guo, Z; He, Z; Liang, Y; Liu, L; Sun, X; Zhang, P; Zhang, Z, 2021) |
| "Adult male Sprague-Dawley rats underwent middle cerebral artery occlusion (MCAO), then received treatment with zileuton or vehicle after the onset of ischemia." | 1.43 | 5-LOX Inhibitor Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the Activation of PI3K/Akt Signaling Pathway. ( Chen, CM; Liang, RS; Shi, SS; Tu, XK; Wang, CH; Yang, WZ; Zhang, HB, 2016) |
| "Hemolysis and consequent release of cell-free hemoglobin (CFHb) impair vascular nitric oxide (NO) bioavailability and cause oxidative and inflammatory processes." | 1.42 | Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. ( Almeida, CB; Conran, N; Costa, FF; Costa, FT; Covas, DT; Leonardo, FC; Souza, LE; Werneck, CC, 2015) |
| "The chronic inflammatory state in sickle cell anemia (SCA) is associated with several factors such as the following: endothelial damage; increased production of reactive oxygen species; hemolysis; increased expression of adhesion molecules by leukocytes, erythrocytes, and platelets; and increased production of proinflammatory cytokines." | 1.40 | Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype. ( Bandeira, IC; Barbosa, MC; Elias, DB; Freitas, MV; Gonçalves, RP; Querioz, JA; Rocha, LB, 2014) |
| "Chronic inflammation is suggested to contribute to the Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and hematologic." | 1.40 | Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. ( Hasselbalch, HC, 2014) |
| "Some sickle cell anemia (SCA) patients suffer significantly worse phenotypes than others." | 1.40 | Mast cell activation syndrome as a significant comorbidity in sickle cell disease. ( Afrin, LB, 2014) |
| "Hydroxyurea therapy was used in 30 patients (31." | 1.36 | Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management. ( Cotton, F; Dedeken, L; Dresse, MF; Ferster, A; Gulbis, B; Heijmans, C; Ketelslegers, O; Lê, PQ; Vanderfaeillie, A; Vermylen, C; Vertongen, F, 2010) |
| "Inflammation was produced by adding carrageenan into a newly formed air pouch and prostaglandins produced." | 1.35 | A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors. ( Anderson, GD; Dufield, DR; Hardy, MM; Masferrer, JL; Pufahl, RA; Zweifel, BS, 2008) |
| "The effect on carrageenan-induced mechanical hyperalgesia, and acetic acid-induced vascular permeability was also determined." | 1.33 | Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats. ( Kulkarni, SK; Patil, CS; Singh, VP, 2005) |
| " Monkeys (n = 6 each group) were dosed with vehicle, 3 or 10 mg/kg ZD2138, or 30 mg/kg Zileuton (p." | 1.29 | The effect of 5-lipoxygenase inhibition on Ascaris antigen (Ag)-induced responses in atopic monkeys. ( Andresen, CJ; Eggler, JF; Smith, WB; Turner, CR; Watson, JW, 1996) |
| "Infection with lymphocytic choriomeningitis virus is associated with marked polyclonal activation of the CD8+ T cell subpopulation." | 1.29 | Characterization of virus-primed CD8+ T cells with a type 1 cytokine profile. ( Christensen, JP; Marker, O; Stenvang, JP; Thomsen, AR, 1996) |
| "Zileuton was approximately 40 times less potent." | 1.28 | Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase. ( Crawley, GC; Foster, SJ; McMillan, RM; Spruce, KE; Walker, ER, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.00) | 18.7374 |
| 1990's | 12 (20.00) | 18.2507 |
| 2000's | 11 (18.33) | 29.6817 |
| 2010's | 27 (45.00) | 24.3611 |
| 2020's | 7 (11.67) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Kulturoglu, G | 1 |
| Ergil, J | 1 |
| Kulturoglu, MO | 1 |
| Yalcindag, A | 1 |
| Onder, EO | 1 |
| Zhou, Y | 1 |
| Lu, Q | 1 |
| Eickhardt-Dalbøge, CS | 1 |
| Ingham, AC | 1 |
| Andersen, LO | 1 |
| Nielsen, HV | 1 |
| Fuursted, K | 1 |
| Stensvold, CR | 1 |
| Larsen, MK | 1 |
| Kjær, L | 1 |
| Christensen, SF | 1 |
| Knudsen, TA | 1 |
| Skov, V | 1 |
| Ellervik, C | 1 |
| Olsen, LR | 1 |
| Hasselbalch, HC | 2 |
| Nielsen, XC | 1 |
| Christensen, JJE | 1 |
| Carden, MA | 1 |
| Little, J | 1 |
| Ndidi, US | 2 |
| Adanho, CSA | 1 |
| Santiago, RP | 2 |
| Yahouédéhou, SCMA | 2 |
| Santana, SS | 1 |
| Mafili, VV | 1 |
| Pitanga, TN | 1 |
| Fonseca, CA | 1 |
| Ferreira, JRD | 1 |
| Adorno, EV | 2 |
| Lyra, IM | 2 |
| Adekile, AD | 1 |
| Barbosa, CG | 1 |
| Goncalves, MS | 2 |
| Garnier, Y | 1 |
| Ferdinand, S | 1 |
| Garnier, M | 1 |
| Cita, KC | 1 |
| Hierso, R | 1 |
| Claes, A | 1 |
| Connes, P | 2 |
| Hardy-Dessources, MD | 2 |
| Lapouméroulie, C | 1 |
| Lemonne, N | 2 |
| Etienne-Julan, M | 2 |
| El Nemer, W | 1 |
| Romana, M | 2 |
| Bewersdorf, JP | 1 |
| Zeidan, AM | 1 |
| Möckesch, B | 1 |
| Tudor Ngo Sock, E | 1 |
| Reminy, K | 1 |
| Skinner, S | 1 |
| Billaud, M | 1 |
| Nader, E | 1 |
| Tressieres, B | 1 |
| Guillot, N | 1 |
| Hue, O | 1 |
| Antoine-Jonville, S | 1 |
| Liu, L | 1 |
| Zhang, P | 1 |
| Zhang, Z | 1 |
| Liang, Y | 1 |
| Chen, H | 1 |
| He, Z | 1 |
| Sun, X | 1 |
| Guo, Z | 1 |
| Deng, Y | 1 |
| Li, JG | 1 |
| Barrero, C | 1 |
| Merali, S | 1 |
| Praticò, D | 1 |
| Wang, Y | 1 |
| Sherchan, P | 1 |
| Huang, L | 2 |
| Akyol, O | 1 |
| McBride, DW | 1 |
| Zhang, JH | 1 |
| Oda, M | 1 |
| Domon, H | 1 |
| Kurosawa, M | 1 |
| Isono, T | 1 |
| Maekawa, T | 1 |
| Yamaguchi, M | 1 |
| Kawabata, S | 1 |
| Terao, Y | 1 |
| Lanaro, C | 1 |
| Franco-Penteado, CF | 1 |
| Silva, FH | 1 |
| Fertrin, KY | 1 |
| Dos Santos, JL | 1 |
| Wade, M | 1 |
| Yerigenahally, S | 1 |
| de Melo, TR | 1 |
| Chin, CM | 1 |
| Kutlar, A | 1 |
| Meiler, SE | 1 |
| Costa, FF | 3 |
| Ansari, J | 1 |
| Moufarrej, YE | 1 |
| Pawlinski, R | 1 |
| Gavins, FNE | 1 |
| da Guarda, CC | 1 |
| Figueiredo, CVB | 1 |
| Carvalho, SP | 1 |
| Fiuza, LM | 1 |
| Oliveira, RM | 1 |
| Carvalho, MOS | 1 |
| Nascimento, VML | 1 |
| Rocha, LC | 1 |
| Bandeira, IC | 1 |
| Rocha, LB | 1 |
| Barbosa, MC | 1 |
| Elias, DB | 1 |
| Querioz, JA | 1 |
| Freitas, MV | 1 |
| Gonçalves, RP | 1 |
| Lopes, FC | 1 |
| Ferreira, R | 1 |
| Albuquerque, DM | 1 |
| Silveira, AA | 1 |
| Costa, R | 1 |
| Soares, R | 1 |
| Conran, N | 2 |
| Afrin, LB | 1 |
| Pulte, ED | 1 |
| McKenzie, SE | 1 |
| Caro, J | 1 |
| Ballas, SK | 1 |
| Rzodkiewicz, P | 1 |
| Gasinska, E | 1 |
| Maslinski, S | 1 |
| Bujalska-Zadrozny, M | 1 |
| Field, JJ | 1 |
| Nathan, DG | 1 |
| Sarray, S | 1 |
| Saleh, LR | 1 |
| Lisa Saldanha, F | 1 |
| Al-Habboubi, HH | 1 |
| Mahdi, N | 1 |
| Almawi, WY | 1 |
| Daak, AA | 1 |
| Elderdery, AY | 1 |
| Elbashir, LM | 1 |
| Mariniello, K | 1 |
| Mills, J | 1 |
| Scarlett, G | 1 |
| Elbashir, MI | 1 |
| Ghebremeskel, K | 1 |
| Almeida, CB | 1 |
| Souza, LE | 1 |
| Leonardo, FC | 1 |
| Costa, FT | 1 |
| Werneck, CC | 1 |
| Covas, DT | 1 |
| Owusu-Ansah, A | 1 |
| Ihunnah, CA | 1 |
| Walker, AL | 1 |
| Ofori-Acquah, SF | 1 |
| Adly, AA | 1 |
| Ismail, EA | 1 |
| Andrawes, NG | 1 |
| Mahmoud, MM | 1 |
| Eladawy, R | 1 |
| Tu, XK | 1 |
| Zhang, HB | 1 |
| Shi, SS | 1 |
| Liang, RS | 1 |
| Wang, CH | 1 |
| Chen, CM | 1 |
| Yang, WZ | 1 |
| Steinberg, MH | 1 |
| Cortes-Burgos, LA | 1 |
| Zweifel, BS | 2 |
| Settle, SL | 1 |
| Pufahl, RA | 2 |
| Anderson, GD | 2 |
| Hardy, MM | 2 |
| Weir, DE | 1 |
| Hu, G | 1 |
| Happa, FA | 1 |
| Stewart, Z | 1 |
| Muthian, S | 1 |
| Graneto, MJ | 1 |
| Masferrer, JL | 2 |
| Lê, PQ | 1 |
| Ferster, A | 1 |
| Cotton, F | 1 |
| Vertongen, F | 1 |
| Vermylen, C | 1 |
| Vanderfaeillie, A | 1 |
| Dedeken, L | 1 |
| Heijmans, C | 1 |
| Ketelslegers, O | 1 |
| Dresse, MF | 1 |
| Gulbis, B | 1 |
| Mothe-Satney, I | 1 |
| Filloux, C | 1 |
| Amghar, H | 1 |
| Pons, C | 1 |
| Bourlier, V | 1 |
| Galitzky, J | 1 |
| Grimaldi, PA | 1 |
| Féral, CC | 1 |
| Bouloumié, A | 1 |
| Van Obberghen, E | 1 |
| Neels, JG | 1 |
| Thornburg, CD | 1 |
| Files, BA | 1 |
| Luo, Z | 1 |
| Miller, ST | 1 |
| Kalpatthi, R | 1 |
| Iyer, R | 1 |
| Seaman, P | 1 |
| Lebensburger, J | 1 |
| Alvarez, O | 1 |
| Thompson, B | 1 |
| Ware, RE | 1 |
| Wang, WC | 1 |
| Lopez-Castejon, G | 1 |
| Luheshi, NM | 1 |
| Compan, V | 1 |
| High, S | 1 |
| Whitehead, RC | 1 |
| Flitsch, S | 1 |
| Kirov, A | 1 |
| Prudovsky, I | 1 |
| Swanton, E | 1 |
| Brough, D | 1 |
| da Silva, NG | 1 |
| Sampaio, SC | 1 |
| Gonçalves, LR | 1 |
| Welliver, RC | 2 |
| Hintz, KH | 1 |
| Glori, M | 1 |
| Patel, NS | 1 |
| Cuzzocrea, S | 2 |
| Chatterjee, PK | 1 |
| Di Paola, R | 2 |
| Sautebin, L | 2 |
| Britti, D | 1 |
| Thiemermann, C | 1 |
| Singh, VP | 1 |
| Patil, CS | 1 |
| Kulkarni, SK | 1 |
| Rao, NL | 1 |
| Dunford, PJ | 1 |
| Xue, X | 1 |
| Jiang, X | 1 |
| Lundeen, KA | 1 |
| Coles, F | 1 |
| Riley, JP | 1 |
| Williams, KN | 1 |
| Grice, CA | 1 |
| Edwards, JP | 1 |
| Karlsson, L | 1 |
| Fourie, AM | 1 |
| Genovese, T | 1 |
| Rossi, A | 1 |
| Mazzon, E | 1 |
| Muià, C | 1 |
| Caminiti, R | 1 |
| Bramanti, P | 1 |
| Hara, J | 1 |
| Fujimura, M | 1 |
| Ueda, A | 1 |
| Myou, S | 1 |
| Oribe, Y | 1 |
| Ohkura, N | 1 |
| Kita, T | 1 |
| Yasui, M | 1 |
| Kasahara, K | 1 |
| Dufield, DR | 1 |
| Little, T | 1 |
| Butler, BD | 1 |
| Snapper, JR | 1 |
| Brigham, KL | 1 |
| Bailie, MB | 1 |
| Dahm, LJ | 1 |
| Peters-Golden, M | 1 |
| Harris, RR | 2 |
| Carter, GW | 3 |
| Roth, RA | 1 |
| Wenzel, SE | 1 |
| Trudeau, JB | 1 |
| Kaminsky, DA | 1 |
| Cohn, J | 1 |
| Martin, RJ | 1 |
| Westcott, JY | 1 |
| Winkler, JD | 1 |
| Fonteh, AN | 1 |
| Sung, CM | 1 |
| Chabot-Fletcher, M | 1 |
| Marshall, LA | 1 |
| Chilton, FH | 1 |
| Bell, RL | 2 |
| Lanni, C | 1 |
| Malo, PE | 1 |
| Brooks, DW | 1 |
| Stewart, AO | 1 |
| Hansen, R | 1 |
| Rubin, P | 1 |
| Nickerson-Nutter, CL | 1 |
| Medvedeff, ED | 1 |
| Turner, CR | 1 |
| Smith, WB | 1 |
| Andresen, CJ | 1 |
| Eggler, JF | 1 |
| Watson, JW | 1 |
| Smith, LJ | 1 |
| Christensen, JP | 1 |
| Stenvang, JP | 1 |
| Marker, O | 1 |
| Thomsen, AR | 1 |
| Larsen, JS | 1 |
| Jackson, SK | 1 |
| Drazen, JM | 1 |
| Wilcox, D | 1 |
| Chies, JA | 1 |
| Nardi, NB | 1 |
| Shin, KH | 2 |
| Nakagawa, H | 2 |
| Tsurufuji, S | 2 |
| McMillan, RM | 1 |
| Spruce, KE | 1 |
| Crawley, GC | 1 |
| Walker, ER | 1 |
| Foster, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)[NCT04839159] | 41 participants (Anticipated) | Interventional | 2012-05-10 | Active, not recruiting | |||
| Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients[NCT02565082] | 64 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort[NCT02887118] | 82 participants (Actual) | Observational | 2015-12-31 | Terminated (stopped due to The recruiting centre was no longer presenting new patients for inclusion) | |||
| Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)[NCT00006400] | Phase 3 | 193 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded). (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 22.56 |
| Placebo | 20.74 |
GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 10.57 |
| Placebo | 14.33 |
Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 28.65 |
| Placebo | 33.36 |
11 reviews available for hydroxyurea and Innate Inflammatory Response
| Article | Year |
|---|---|
Emerging disease-modifying therapies for sickle cell disease.
Topics: Anemia, Sickle Cell; Antioxidants; Antisickling Agents; Blood Coagulation; Clinical Trials as Topic; | 2019 |
Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.
Topics: Bone Marrow; Clinical Trials as Topic; Combined Modality Therapy; DNA Methylation; Drugs, Investigat | 2020 |
Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Communication; Cerebrovascular Disorders; Disease Pro | 2018 |
Advances in sickle cell therapies in the hydroxyurea era.
Topics: Anemia, Sickle Cell; Animals; Cell Adhesion; Genetic Therapy; Hematopoietic Stem Cell Transplantatio | 2014 |
Inflammatory targets of therapy in sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Humans; Hydroxyurea; Inflammation; Signal Tr | 2016 |
Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Erythrocyte Membrane; Female; Hemoglobin, Sickle; Humans; Hy | 2008 |
Inflammation and airway reactivity.
Topics: Aerosols; Animals; Asthma; Disease Models, Animal; Dogs; Endotoxins; Granulocytes; Guinea Pigs; Hist | 1984 |
Inhibition of CoA-independent transacylase reduces inflammatory lipid mediators.
Topics: Acyltransferases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Humans; Hydroxy | 1995 |
Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents.
Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Humans; Hydroxyurea | 1996 |
Antileukotriene therapy for asthma.
Topics: Asthma; Humans; Hydroxyurea; Inflammation; Leukotrienes; Lipoxygenase Inhibitors | 1996 |
New directions in asthma drug therapy.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Chromones; Humans; Hydroxyur | 1998 |
6 trials available for hydroxyurea and Innate Inflammatory Response
| Article | Year |
|---|---|
Oxidative stress, inflammation, blood rheology, and microcirculation in adults with sickle cell disease: Effects of hydroxyurea treatment and impact of sickle cell syndrome.
Topics: Adult; Anemia, Sickle Cell; Biomarkers; Blood Viscosity; Female; Humans; Hydroxyurea; Inflammation; | 2021 |
Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Bilirubin; Biomarkers; Blood Glucose; Child; Child, Preschoo | 2019 |
Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Erythropoietin; Female; Hemoglobi | 2014 |
Omega 3 (n-3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; C-Reactive Protein; Case-Control Studies; Cell | 2015 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.
Topics: Adolescent; Adult; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Bronchoconstri | 1995 |
43 other studies available for hydroxyurea and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
The effects of hydroxyurea on proinflammatory cytokine and tissue histopathology in an experimental sepsis model.
Topics: Animals; Cytokines; Hydroxyurea; Inflammation; Rats; Sepsis; Tumor Necrosis Factor-alpha | 2022 |
Hydroxyurea protects against diabetic cardiomyopathy by inhibiting inflammation and apoptosis.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Diabetes Mellitus, Experimental; Diabetic Cardiom | 2022 |
The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment.
Topics: Gastrointestinal Microbiome; Humans; Hydroxyurea; Inflammation; Interferon-alpha; Polycythemia Vera | 2023 |
Effect of N(Epsilon)-(carboxymethyl)lysine on Laboratory Parameters and Its Association with
Topics: Anemia, Sickle Cell; Antisickling Agents; Aspartate Aminotransferases; beta-Globins; Child; Creatini | 2019 |
Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties.
Topics: Adolescent; Anemia, Sickle Cell; Cell-Derived Microparticles; Endothelium, Vascular; Female; Humans; | 2020 |
5-Lipoxygenase inhibition reduces inflammation and neuronal apoptosis via AKT signaling after subarachnoid hemorrhage in rats.
Topics: Administration, Oral; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Brain Injuries; Chromones; Di | 2021 |
Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer's phenotype.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Diet; DNA Methylation; Female; | 2017 |
Naja sputatrix Venom Preconditioning Attenuates Neuroinflammation in a Rat Model of Surgical Brain Injury via PLA2/5-LOX/LTB4 Cascade Activation.
Topics: Animals; Arachidonate 5-Lipoxygenase; Biomarkers; Brain; Brain Edema; Brain Injuries; Elapid Venoms; | 2017 |
Topics: Animals; Aorta; Arachidonic Acid; Aspirin; Cell Adhesion Molecules; DNA, Bacterial; Endothelial Cell | 2017 |
A thalidomide-hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes.
Topics: Anemia, Sickle Cell; Animals; Cytokines; Disease Models, Animal; Fetal Hemoglobin; Hydroxyurea; Infl | 2018 |
Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype.
Topics: Adult; Aged; Anemia, Sickle Cell; beta-Globins; Case-Control Studies; Chromosomes, Human; Chronic Di | 2014 |
Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
Topics: Chronic Disease; Comorbidity; Humans; Hydroxyurea; Inflammation; Interferon alpha-2; Interferon-alph | 2014 |
In vitro and in vivo anti-angiogenic effects of hydroxyurea.
Topics: Anemia, Sickle Cell; Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Human Umbi | 2014 |
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Caseins; Chromogranin A; Cohort Studies; Female; He | 2014 |
Antinociceptive properties of esculetin in non-inflammatory and inflammatory models of pain in rats.
Topics: Analgesia; Analgesics; Animals; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Hydroxyurea; Hy | 2015 |
Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans; Hydroxyurea; Infant | 2015 |
Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea.
Topics: Anemia, Sickle Cell; Animals; Cell Movement; Cyclic N-Oxides; Disease Models, Animal; Free Radical S | 2015 |
Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Antisickling Agents; Apoptosis; Biomarkers; C-Reactive | 2016 |
5-LOX Inhibitor Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the Activation of PI3K/Akt Signaling Pathway.
Topics: Animals; Arachidonate 5-Lipoxygenase; Brain; Brain Ischemia; Hydroxyurea; Infarction, Middle Cerebra | 2016 |
CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
Topics: Administration, Oral; Animals; Arachidonate 5-Lipoxygenase; Blotting, Western; Cell Line; Disease Mo | 2009 |
Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management.
Topics: Adolescent; Africa; Anemia, Sickle Cell; Antisickling Agents; Belgium; Bone Marrow Transplantation; | 2010 |
Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice.
Topics: Adipocytes; Adipose Tissue; Animals; Arachidonate 5-Lipoxygenase; Cell Line; Chemokines; Cytokines; | 2012 |
Deubiquitinases regulate the activity of caspase-1 and interleukin-1β secretion via assembly of the inflammasome.
Topics: Animals; Carboxypeptidases; Caspase 1; Endopeptidases; Fibroblast Growth Factor 1; Fibroblast Growth | 2013 |
Inhibitory effect of Crotalus durissus terrificus venom on chronic edema induced by injection of bacillus Calmette-Guérin into the footpad of mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; BCG Vaccine; Chronic Disease; Crotalid Venoms; Cro | 2013 |
Zileuton reduces respiratory illness and lung inflammation, during respiratory syncytial virus infection, in mice.
Topics: Animals; Bronchoalveolar Lavage Fluid; Cell Count; Disease Models, Animal; Hydroxyurea; Inflammation | 2003 |
Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton.
Topics: Animals; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Hydroxyurea; Inflammation; Intercellul | 2004 |
Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats.
Topics: Acetates; Acetic Acid; Analgesics; Animals; Capillary Permeability; Carrageenan; Cyclopropanes; Dose | 2005 |
Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Ascitic Fluid; Benzothiazoles; D | 2007 |
Effects of zileuton and montelukast in mouse experimental spinal cord injury.
Topics: Acetates; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Cyclooxygenase 2; Cyclopropanes; Cysteine | 2008 |
Effect of pressure stress applied to the airway on cough-reflex sensitivity in Guinea pigs.
Topics: Animals; Biomechanical Phenomena; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Broncho | 2008 |
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Topics: Air; Animals; Arachidonate 5-Lipoxygenase; Biological Assay; Calcimycin; Carrageenan; Cell Line, Tum | 2008 |
Pharmacological intervention to the inflammatory response from decompression sickness in rats.
Topics: Animals; Cyclooxygenase Inhibitors; Decompression Sickness; Hydroxyurea; Indoles; Indomethacin; Infl | 2008 |
Leukotrienes and alpha-naphthylisothiocyanate-induced liver injury.
Topics: 1-Naphthylisothiocyanate; Acetamides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcimycin; | 1995 |
Preclinical and clinical activity of zileuton and A-78773.
Topics: Animals; Bronchial Spasm; Guinea Pigs; Hydroxyurea; Inflammation; Leukotriene B4; Lipoxygenase Inhib | 1993 |
The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chronic Disease; Disease | 1996 |
The effect of 5-lipoxygenase inhibition on Ascaris antigen (Ag)-induced responses in atopic monkeys.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Helminth; Ascaris suum; Bronchoalveolar | 1996 |
Characterization of virus-primed CD8+ T cells with a type 1 cytokine profile.
Topics: Animals; Cytotoxicity, Immunologic; Female; Hydroxyurea; Inflammation; Integrin alpha4beta1; Integri | 1996 |
The role of tissue mast cells in polyacrylamide gel-induced inflammation in mice.
Topics: Acrylic Resins; Animals; Anti-Inflammatory Agents; Dinoprostone; Hydroxyurea; Inflammation; Leukocyt | 1998 |
Sickle cell disease: a chronic inflammatory condition.
Topics: Anemia, Sickle Cell; Animals; Chronic Disease; Humans; Hydroxyurea; Inflammation; Mice; Mice, Transg | 2001 |
Analysis of the correlation between collagen and desoxyribonucleic acid syntheses under the influence of hydroxyurea in the inflammatory connective tissue.
Topics: Animals; Collagen; Connective Tissue; Depression, Chemical; DNA; Hydroxyurea; Inflammation; Male; Ra | 1976 |
Rebound of vascular permeability response and its inhibition by hydroxyurea in granulomatous inflammation following withdrawal of glucocorticoid therapy.
Topics: Animals; Capillary Permeability; Carrageenan; Granuloma; Hydrocortisone; Hydroxyurea; Inflammation; | 1975 |
Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Bronchocon | 1992 |